BARDA rejects Pluristem's request for radiation study funding

The U.S. Biomedical Advanced Research and Development Authority has rejected Pluristem Therapeutics’ request for funding to conduct a study. Pluristem wanted the money to show its cell therapy PLX-R18 is better than standard of care at treating acute radiation syndrome.

BARDA rejects Pluristem's request for radiation study funding
The U.S. Biomedical Advanced Research and Development Authority has rejected Pluristem Therapeutics’ request for funding to conduct a study. Pluristem wanted the money to show its cell therapy PLX-R18 is better than standard of care at treating acute radiation syndrome.